Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs. Issue 2 (28th October 2016)

• Record Type: Journal Article
• Authors: Meister, Michael Torsten; Boedicker, Cathinka; Graab, Ulrike; Hugle, Manuela; Hahn, Heidi; Klingebiel, Thomas; Fulda, Simone
• Is Part Of: Cancer letters. Volume 381:Issue 2(2016)
• Page Start: 287
• Page End: 295
• Publication Date: 2016-10-28
• Subjects: Apoptosis -- Cell death -- Arsenic trioxide -- Noxa -- Hedgehog -- Rhabdomyosarcoma; ATO arsenic trioxide -- CI combination index -- FCS fetal calf serum -- FDA Food and Drug Administration -- Hh Hedgehog -- HPI Hh pathway inhibitors -- MDR multi-drug resistance -- MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide -- PI propidium iodide -- Ptch patched -- RMS rhabdomyosarcoma -- Smo smoothened -- SuFu suppressor of fused -- VCR vincristine -- zVAD.fmk N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.07.007
• Languages: English
• ISSNs: 0304-3835

Abstract

Highlights: ATO reduces cell viability and clonogenic survival and triggers apoptosis in RMS cells. ATO upregulates Noxa, which is required for ATO-induced cell death. ATO synergizes with antimicrotubule drugs to trigger apoptosis. Abstract: The prognosis of metastatic or relapsed rhabdomyosarcoma (RMS) is poor, highlighting the need of new treatment options. In the present study, we evaluated the in vitro efficacy of arsenic trioxide (ATO) in RMS, a FDA-approved drug used in pediatric leukemia. Here, we report that ATO exerts antitumor activity against RMS cells both as single agent and in combination with microtubule-targeting drugs. Monotherapy with ATO reduces cell viability, triggers apoptosis and suppresses clonogenic survival of RMS cells, at least in part, by transcriptional induction of the proapoptotic BH3-only protein Noxa. siRNA-mediated knockdown of Noxa significantly rescues ATO-mediated cell death, demonstrating that Noxa is required for cell death. Also, ATO suppresses endogenous Hedgehog (Hh) signaling, as it significantly reduces Gli1 transcriptional activity and expression levels of several Hh target genes. Furthermore, we identify synergistic induction of apoptosis by ATO together with several antimicrotubule agents including vincristine (VCR), vinblastine and eribulin. The addition of the broad-range caspase inhibitor zVAD.fmk or overexpression of the antiapoptotic protein Bcl-2 significantly reduce ATO/VCR-induced cell death, indicating that the ATO/VCR combination triggers caspase-dependent apoptosis via the mitochondrial pathway. In summary, ATO exerts antitumor activity against RMS, especially in combination with antimicrotubule drugs. These findings have important implications for the development of novel therapeutic strategies for RMS.